Catherine Skari

TIF WEBINAR SERIES 2026 | Bridging the Communication Gap in Haemoglobinopathy Care

This year, the Thalassaemia International Federation (TIF) launches a transformative quarterly webinar series designed to strengthen dialogue between patients, families,…

wAIHA | Rilzabrutinib Receives FDA Breakthrough Therapy Designation

Warm autoimmune haemolytic anaemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells, leading to…

INTERNATIONAL THALASSAEMIA DAY 2026 | A New Theme for Global Action

RARE DISEASE DAY 2026 | More Than You Can Imagine

This year’s theme, “More Than You Can Imagine,” reminds us that rare diseases are far more common, complex, and impactful…

wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results

  wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red…

THALASSAEMIA IN THE AMERICAS | New TIF White Paper Calls for Coordinated Action and Equity in Care

Developed in the context of the 1st TIF Pan-American Conference on Thalassaemia and Other Haemoglobin Disorders, held in Washington, D.C.…

THE MENA THALASSAEMIA EXPERIENCE: A Two-Day, In-Person Masterclass

IMPORTANT: In light of the current unrest in the Middle East and the evolving regional situation, this masterclass is postponed…

U.S. EXIT FROM WHO | Implications for Global Health Cooperation and Preparedness

The U.S. government said the decision was based on concerns about how the WHO handled previous global health emergencies, particularly…

SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit

The study explores the potential of memantine, a medication that has been safely used for many years in the treatment…